All In Biotech

Drug Trial Radar · NCT07896109

A Research Study to Check the Safety of NNC9836-0001 When Given to Healthy Participants and Participants With Type 2 Diabetes

A Phase 1 Randomised, Double-blinded, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of NNC9836-0001 Administered to Healthy Participants and Participants With Type 2 Diabetes

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 121 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

121

Planned (sponsor's estimate)

Start

Oct 22, 2026

Primary completion

Jul 26, 2028

Study completion Jul 26, 2028

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Oct 26, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 25 years, up to 69 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this clinical study is to determine if the study medicine NNC9836-0001 is safe and tolerable in healthy participants with overweight or obesity or who have type 2 diabetes (T2D). Participants will either get the study medicine NNC9836-0001 or placebo. Which treatment participants get is decided by chance. NNC9836-0001 is a new medicine aimed to treat type 2 diabetes.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

  • NNC9836-0001Drug

    NNC9836-0001 will be administered subcutaneously.

  • Placebo (NaCl)Drug

    Placebo (NaCl) will be administered subcutaneously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Single ascending dose (SAD): Number of Treatment emergent adverse events (TEAEs)Time frame: From dosing (day 1) until week 26
  2. Multiple ascending dose (MAD): Number of TEAEsTime frame: From dosing (day 1) to week 34

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Profil Institut für Stoffwechselforschung GmbH

    Neuss, Germany · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.